3-methyl-2-vinylfuran | 52559-01-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: 3-methyl-2-vinylfuran
• 英文别名: 2-ethenyl-3-methylfuran
• CAS: 52559-01-0
• 化学式: C₇H₈O
• 分子量: 108.14
• InChiKey: WAVMEWSWFALXSL-UHFFFAOYSA-N

物化性质

• 沸点：
  120.9±9.0 °C(Predicted)
• 密度：
  0.944±0.06 g/cm3(Predicted)
• 保留指数：
  1161;1162;1164;1164;1183

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  13.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  6,10-二甲基-5,9-十一双烯-2-酮 、 iodo(2-(3-methylfur-2-yl)ethyl)triphenylphosphorane 在 18-冠醚-6 、 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以33.333%的产率得到
  参考文献：
  名称：

  通过膦-钯催化合成呋喃天然产物的统一方法

  摘要：

  多烷基呋喃在自然界中广泛存在，通常发挥重要的生物学作用。尽管合成四取代呋喃的方法有很多，但四烷基呋喃的构建仍然很重要。生物活性呋喃天然产物中烷基的普遍存在，加上四烷基呋喃所需的生物活性，需要一种多烷基呋喃的通用合成方案。本文描述了一种 Michael-Heck 方法，使用顺序膦-钯催化，从容易获得的前体制备各种聚烷基呋喃。该方法的多功能性通过属于不同类别的九种不同的多烷基化呋喃天然产物（即呋喃萜玫瑰呋喃、倍半糖呋喃和米卡尼呋喃）的全合成来说明；海洋天然产物plakorsin A、B、D和plakorsin D甲酯；以及呋喃脂肪酸3D5和氢木霉素。

  DOI：

  10.1002/anie.202015232

文献信息

• Novel allylic amines
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0186915A2

  公开（公告）日：1986-07-09

  This invention relates to novel β-methylenefuranethan- amines which are mechanism-based inhibitors of dopamine beta-hydroxylase useful as antihypertensive agents.

  本发明涉及新型β-亚甲基呋喃乙胺，它是多巴胺β-羟化酶的机理抑制剂，可用作降压药。
• BIOKOMPOSIPLATTE
  申请人：RESOPAL GMBH

  公开号：EP2621979A1

  公开（公告）日：2013-08-07
• BIOKOMPOSITPLATTE
  申请人：RESOPAL GMBH

  公开号：EP2621979B1

  公开（公告）日：2015-05-06
• BIOCOMPOSITE PANEL
  申请人：Schaefer Donald

  公开号：US20130295399A1

  公开（公告）日：2013-11-07

  A biocomposite panel comprising a) at least one natural fiber and b) at least one thermosetting biopolymer, wherein the biocomposite panel has a residual moisture content, based on the total weight thereof, of less than 8.0 wt %, the biocomposite panel comprises at least two sheets of paper, the biopolymer includes a furan resin, and the weight proportion of the biopolymer, based on the total weight of the biocomposite panel, is at least 20.0 wt %.
• COMBINATION PRODUCT FOR THE INDUCTION AND/OR MAINTENANCE OF GENERAL ANESTHESIA
  申请人：BLUMENTECH, S.L.

  公开号：US20210186927A1

  公开（公告）日：2021-06-24

  The state of general anesthesia (GA) is essential to many surgical and medical procedures. This state is characterized by loss of consciousness, deep analgesia and suppression of movements. GA is rarely achieved with a single drug, usually requiring the combination of various pharmacological agents. Each drug can interact with one or more molecular targets affecting neuronal excitability and synaptic transmission in multiple regions of the CNS. Agonists of the μ-opioid receptor are commonly used in GA to cause analgesia, but not to induce or maintain loss of consciousness or movement suppression. Additionally, agonists of the μ-opioid receptor can cause serious unwanted side effects, e.g. respiratory depression. The present invention provides alternative combination products based on K-opioid receptor agonists. These combination products unexpectedly induced loss of consciousness, and were able to achieve and maintain GA. Furthermore, the combination products suppressed pain perception without the need of a μ-opioid receptor agonist. The combination of Salvinorin A, a selective κ-opioid receptor agonist, with Diazepam or Medetomidine surprisingly led to rapid consciousness, deep analgesia and movement suppression. This combination was found to effectively induce and maintain a state of general anesthesia.